Griswold et al., 2016 - Google Patents

Design and engineering of deimmunized biotherapeutics

Griswold et al., 2016

View PDF
Document ID
7940567926612622001
Author
Griswold K
Bailey-Kellogg C
Publication year
Publication venue
Current opinion in structural biology

External Links

Snippet

Highlights•Immunogenicity as a risk factor for biotherapeutic agents.•Antibody epitope deletion as a strategy to evade antidrug antibodies.•T cell epitope deletion as a strategy to silence the antidrug immune response.•Multi-objective protein design algorithms to facilitate …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Similar Documents

Publication Publication Date Title
Griswold et al. Design and engineering of deimmunized biotherapeutics
Sauna et al. Evaluating and mitigating the immunogenicity of therapeutic proteins
Kaplon et al. Antibodies to watch in 2021
Lazar et al. A molecular immunology approach to antibody humanization and functional optimization
Dimitrov Therapeutic antibodies, vaccines and antibodyomes
Jawa et al. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation
Mazor et al. Strategies to reduce the immunogenicity of recombinant immunotoxins
CN103796679B (en) Anti-α synapse nucleoprotein binding molecule
CN102317316B (en) Human anti-alpha-synuclein autoantibodies
De Groot et al. Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics
CN107001472A (en) There is specific binding molecule and application thereof to CD73
CN110366560A (en) Anti- B7-H4 antibody, its antigen-binding fragment and its medical usage
US10208126B2 (en) Methods of treating aplastic anemia by administering anti-CD26 antibodies
EA029419B1 (en) Neutralizing anti-ccl20 antibodies
TW201828991A (en) Antibody drug conjugates for ablating hematopoietic stem cells
Zajc et al. Driving CARs with alternative navigation tools–the potential of engineered binding scaffolds
Zhang et al. Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples
Gehlsen et al. Pharmacokinetics of engineered human monomeric and dimeric CH2 domains
Beck et al. 6th Annual European Antibody Congress 2010: November 29–December 1, 2010, Geneva, Switzerland
Yachnin et al. MHCEpitopeEnergy, a flexible Rosetta-based biotherapeutic deimmunization platform
Klinguer-Hamour et al. World antibody-drug conjugate summit, October 15–16, 2013, San Francisco, CA
Beck et al. 8th annual european antibody congress 2012: November 27–28, 2012, Geneva, Switzerland
Burkovitz et al. Computational identification of antigen-binding antibody fragments
Kim et al. Isolation and characterization of single domain antibodies from banded houndshark (Triakis scyllium) targeting SARS-CoV-2 spike RBD protein
Brennan et al. Nonclinical safety testing of biopharmaceuticals–Addressing current challenges of these novel and emerging therapies